ARCHIVES

The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power

This article is from The Cancer Letter archive.

Vol. 40 No. 41 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Phase II ThermoDox Trial Demonstrates Positive Response

August 29, 2014

NCI “Rescues” 31 Grants From Other Institutes, Funds Them at 41.6 Million; Scores Were 148-270

August 9, 1974

Report Urges Changes To Cut Activation Times For NCI Phase III Trials.

April 9, 2010

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

Barnett Kramer Next Director Of NCI Division of Cancer Prevention

July 29, 2011

In Brief: Rhoads, Schmidt Bow Out – Amos, Krim Possible Replacements; Sibal acting Virology Director

January 27, 1978